Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.
The line-up includes a late-breaking abstract oral presentation of results from BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management), a Phase 3 trial for which Arena reported positive, highly significant top-line results in September. Arena will also present new data analyses from lorcaserin's successful Phase 3 pivotal program in oral and poster sessions. In an independent clinical symposium, expert academic scientists and physicians will spotlight the 5HT-2C mechanism for weight management.
The positive results from our Phase 3 pivotal program highlight lorcaserin's potential to provide physicians with a treatment option that combines three important attributes - efficacy, safety and tolerability
"- critical to broad applicability in the majority of their patients to help manage weight and improve cardiometabolic health," stated William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer. "The breadth of presentations featuring lorcaserin at The Obesity Society's annual scientific meeting speaks to the strong interest physicians have in this drug candidate."
Study explores tocotrienols' neuroprotective effects in obesity-related cognitive decline